Computational Antibody Discovery Symposium: Closing remarks by Andrew Buchanan (AstraZeneca)

Computational Antibody Discovery: State of the Art, June 22, 2023
Concluding remarks - Andrew Buchanan, AstraZeneca
Agenda
Introduction - Janice Reichert (The Antibody Society); Konrad Krawczyk (Natural Antibody); Andrew Buchanan (AstraZeneca)
Speaker 1) Pietro Sormanni (University of Cambridge). Third-generation approaches of antibody discovery and optimization
2) Tzvika Hartman (Biolojic Design). AI-driven design of smart therapeutics
3) Victor Greiff (University of Oslo). Computational developability profiling of antibody repertoire data
4) Sandeep Kumar (Boehringer Ingelheim). Biopharmaceutical Informatics: Syncretic use of computation and experimentation in discovery and development of biotherapeutics
5) Ben Holland (Antiverse). Machine learning-based design of antibodies against difficult targets
Panel discussion: Panelists provided their opinions and insights on these questions:
1. What properties are more urgent to be able to design in silico - binding specificity, developability or something else?
2. What performance should computational antibody design achieve to improve upon established protocols?
3. What are the biggest hurdles for computational antibody discovery to achieve its full potential (models, data or something else)?
4. How could industry and academia complement each other to solve the problem of computationally designing antibodies?
5. What role does big tech/biopharma have to play in development and adoption of computational antibody design paradigms?
Concluding remarks (Andrew Buchanan, AstraZeneca)